Clinical Trials Logo

ER Positive Breast Cancer clinical trials

View clinical trials related to ER Positive Breast Cancer.

Filter by:

NCT ID: NCT02345772 Terminated - Clinical trials for HER2-positive Breast Cancer

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

Neohttp
Start date: July 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Hormonal therapy administered before surgery in ER-positive and HER2-positive patients with breast cancer.

NCT ID: NCT01361945 Withdrawn - Breast Cancer Clinical Trials

AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer

Start date: July 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find out what effects, administering infusions of AUY922 with hormonal therapy (letrozole) and oral targeted drug (lapatinib) will have on the patients with advanced breast cancer known as ER+ HER2 +.

NCT ID: NCT00965939 Completed - Clinical trials for ER-positive Breast Cancer

An Observational Study to Assess Response to Tamoxifen in Breast Cancer Patients

CYPTAMBRUT-2
Start date: February 2009
Phase: N/A
Study type: Observational

CYPTAM-BRUT 2 is a prospective, multicentric study including postmenopausal women receiving tamoxifen for metastatic, locally advanced (stage IIIB/C) or in the neoadjuvant setting for measurable estrogen-receptor positive breast cancers. The primary endpoint is the difference in efficacy of tamoxifen, defined as the objective response rate using RECIST criteria, between women with a normal versus low Tamoxifen Activity Score (TAS) after 3-6 months of tamoxifen use. The TAS score is based on the presence of genetic variations and drug interactions. Secondary endpoints are time to progression, clinical benefit, serum metabolite concentrations, endometrial changes and menopausal symptoms. Patients using tamoxifen in the neoadjuvant setting needs being operated between 4-6 months following the start of tamoxifen.